Samanta Yubero-Lahoz *

Autora invitada por SIIC

El trabajo contribuye a resolver cuál es la alteración del CYP2D6 en humanos producida por el consumo de éxtasis.

DIFERENCIAS ENTRE LOS SEXOS EN LA INHIBICION DEL CYP2D6 INDUCIDA POR EL CONSUMO DE EXTASIS

Se determinó el grado de alteración de las isoenzimas hepáticas CYP2D6 y CYP3A4 después del consumo de éxtasis, y el tiempo que tarda en volver a su actividad basal, en ambos sexos.

*Samanta Yubero-Lahoz
describe para SIIC los aspectos relevantes de su trabajo
SEX DIFFERENCES IN 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA; ECSTASY)-INDUCED CYTOCHROME P450 2D6 INHIBITION IN HUMANS
Institución principal de la investigación
*Universitat Pompeu Fabra (cexs-upf), Barcelona, España
Imprimir nota

Comprar este artículo
Otros artículos escogidos

Referencias bibliográficas
1. Parrott AC. Human psychopharmacology of ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol 16: 557-77, 2001.
2. De la Torre R, Farré M, Roset PN, et al. Human pharmacology of MDMA. Ther Drug Monit 26(2):137-44, 2004.
3. Mas M, Farré M, De la Torre R, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290(1):136-45, 1999.
4. Camí J, Farré M. Drug addiction. New Engl J Med 349:975-986, 2003.
5. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 340(8816):384-7, 1992.
6. Capela JP, Carmo H, Remião F, et al. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol 39:210–271, 2009.
7. Murphy PN, Wareing M, Fisk JE, et al. Executive working memory deficits in abstinent ecstasy/MDMA users: a critical review. Neuropsychobiology 60(3-4):159-75, 2009.
8. Gudelsky GA, Yamamoto BK. Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacol Biochem Behav 90(2):198–207, 2008.
9. Baumann MH, Rothman RB. Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA). Int Rev Neurobiol 88:257-96, 2009.
10. De la Torre R, Farré M, Roset PN, et al. Pharmacology of MDMA in humans. Ann N Y Acad Sci 914:225-37, 2000.
11. Segura M, et al. 3,4-dihydroxymethamphetamine (HHMA). A major in vivo MDMA metabolite in humans. Chem Res Toxicol 14:1203-08, 2001.
12. Easton N, et al. Synthesis, in vitro formation, and behavioural effects of glutathione regioisomers of alpha-methyldopamine with relevance to MDA and MDMA (ecstasy). Brain Res 987:144-54, 2003.
13. Hiramatsu M, Kumagai Y, Unger SE, et al. Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J Pharmacol Exp Ther 254:521-7, 1990.
14. Perfetti X, O'Mathúna B, Pizarro N, et al. Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion. Drug Metab Dispos 37(7):1448-55, 2009.
15. Capela JP, Macedo C, Branco PS, et al. Neurotoxicity mechanisms of thioether ecstasy metabolites. Neuroscience 146(4):1743-57, 2007.
16. Monks TJ, Jones DC, Bai F, Lau SS. The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity. Ther Drug Monit 26(2):132-6, 2004.
17. Tucker GT, Lennard MS, Ellis SW, et al. The demethylenation of the methylenedioxymethamphetamine (‘ecstasy’) by cytochrome P4502D6 by human debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47(7):1151-6, 1994.
18. Kreth K, Kovar K, Schwab M, et al. Identification of the human cytochromes P450 involved in the oxidative metabolism of ‘ecstasy’-related designer drugs. Biochem Pharmacol 59(12):1563-71, 2000.
19. Meyer MR, Peters FT, Maurer HH. The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers. Drug Metab Dispos 36(11):2345-54, 2008.
20. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Nauny-Schmiedeberg’s Arch Pharmacol 369:23-37, 2004.
21. Bogni A, Monshouwer M, Moscone A, et al. Sibstrate specific metabolism by polymorphinc cythochrome P450 2D6 alleles. Toxicol In Vitro 19:621-29, 2005.
22. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 48(11):689-723, 2009.
23. McElroy S, Sachse C, Brockmoller J, et al. CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting. AAPS PharmSci 2(4):E33, 2000.
24. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P4502D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg’s Arch Pharmacol 369:23–37, 2004.
25. Woktczak A, Rychlik-Sych M, Krochmalska-Ulacha E, et al. CYP2D6 phenotyping with dextormethorphan. Pharmacological Reports 59:734-8, 2007.
26. Yu A, Haining RL. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos 29:1514-20, 2001.
27. Frank D, Jaehde U, Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 63:321–333, 2007.
28. Spatzenegger M, Jaeger W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metabolism Reviews 27(3):397-417, 1995.
29. Ducharme J, Abdullah S, Wainer IW. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B Biomed Appl 678(1):113-28, 1996.
30. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3(4):197-204, 1993.
31. Chladek J, Zimova G, Beranek M, et al. In-vivo indices of CYP2D6 activity: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma. Eur J Clin Pharmacol 56:651-57, 2000.
32. Greene SL, Dargan PI, O'Connor N, Jones AL, Kerins M. Multiple toxicity from 3,4-methylenedioxymethamphetamine ("ecstasy"). Am J Emerg Med 21(2):121-4, 2003.
33. Gilhooly TC, Daly AK. CYP2D6 deficiency, a factor in ecstasy related deaths? Br J Clin Pharmacol 54:69-70, 2002.
34. De la Torre R, Farré M, Ortuño J, et al. Non-linear pharmacokinetics of MDMA (“ecstasy”) in humans. Br J Clin Pharmacol 49(2):104-9, 2000.
35. Farré M, De la Torre R, Mathúna BO, et al. Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology 173:364-75, 2004.
36. Baumann MH, Zolkowska D, Kim I, et al. Effects of dose and route of administration on pharmacokinetics of (±)-3,4-methylenedioxymethamphetamine in the rat. Drug Metab Dispos 37(11):2163-70, 2009.
37. Yang J, Jamei M, Heydari A, et al. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol 20:842-9, 2006.
38. De la Torre, Farré M. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 25(10):505-8, 2004.
39. Delaforge M, Jaouen M, Bouielle G. Inhibitory metabolite complex formation of methylenedioxymethamphetamine with rat and human cytochrome P450. Particular involvement of CYP 2D. Environ Toxicol Pharmacol 7:153-8, 1999.
40. Mathúna OB, Farré M, Rostami-Hodjegan A, et al. The consequences of 3,4-Methylenedioxymethamphetamine Induced CYP2D6 Inhibition in Humans. J Clin Psychopharmacol 28:525-31, 2008.
41. Kolbrich EA, Goodwin RS, Gorelick DA, et al. Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit 30(3):320-32, 2008.
42. Torrens M, Serrano D, Astals M, et al. Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical interview for DSM-IV. Am J Psychiatry 161:1231-7, 2004.
43. Schmid B, Bircher J, Preisig R, et al. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38:618-24, 1985.
44. Parrott AC. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology 173:234-41, 2004.
45. De la Torre R, Farré M, Mathúna, et al. MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and nine CYP2D6 extensive metabolisers. Eur J Clin Pharmacol 61:551-4, 2005.
46. Pizarro N, Ortuno J, Farré M, et al. Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analisis of enantiomers by capillary electrophoresis. J Anal Toxicol 26:157-65, 2002.
47. Usansky JI, Desai A, Tang-Liu D. Pharmacokinetic and pharmacokinetic resources [online]. Available from URL: http:// www.boomer.org/pkin [Accessed 2009 Oct 13].
48. De la Torre R, Farré M, Navarro M, et al. Clinical pharmacokinetics of amfetamine and related substances: monitoring in convencional and non-conventional matrices. Clin Pharmacokinet 43(3):157-85, 2004.
49. Labbe L, Sirois C, Pilote S, et al. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 10:425-38, 2000.
50. Funck-Brentano C, Boëlle PY, Verstuyft C, Bornert C, Becquemont L, Poirier JM. Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. Eur J Clin Pharmacol 61:821-9, 2005.
51. Kirchheiner J, Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochimica et Biopjysica Acta 489-94, 2007.
52. Soar K, Turnerr JJ, Parrott AC. Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors. J Psychopharmacol 20:417-24, 2006.
53. Martín-Santos R, Torrens M, Poudevida S, Langohr K, Cuyás E, Pacifici R, Farré M, Pichini S, De la Torre R. 5-HTTLPR polymorphism, mood disorders and MDMA use in a 3-year follow-up study. Addict Biol 15(1):15-22, 2010.
54. Ozdemir M, Crewe Kh, Tücker GT, et al. Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH. J Clin Pharmacol 44:1398-404, 2004.
55. McCune JS, Lindley C, Decker JL, et al. Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan. J Clin Pharmacol 41:723, 2001.
56. Kashuba AD, Nafziger AN, Kearns GL, et al. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics 8(5):403-10, 1998.
57. Franconi F, Brunelleschi S, Steardo L, et al. Gender differences in drug responses. Pharmacol Res 55(2):81-95, 2007.
58. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet 42(2):107-21, 2003.
59. Anderson GD. Gender differences in pharmacological response. Int Rev Neurobiol 83:1-10, 2008.
60. Bock KW, Schrenk D, Forster A, et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 4:209-18, 1994.
61. Hägg S, Spigset O, Dahlqvist R. Influence of gender and oral contraceptives on CYP2D6 and CYP2C18 activity in healthy volunteers. Br J Clin Pharmacol 51(2):169-73, 2001.
62. Segura M, Farré M, Pichini S, et al. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans. Clin Pharmacokinet 44(6):649-60, 2005.
63. Kreth K, Kovar K, Schwab M, et al. Identification of the human cytochromes P450 involved in the oxidative metabolism of “ecstasy”-related designer drugs. Biochem Pharmacol 59(12):1563-71, 2000.

Otros artículos de Samanta Yubero-Lahoz

Pardo-Lozano R, Farré M, Yubero-Lahoz S, O’Mathúna B, Torrens M, Mustata C, Pérez-Mañá C, Langohr K, Cuyàs E, Carbó M, De la Torre R. Clinical Pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”): The influence of gender and genetics (COMT, CYP2D6, 5-HTT). Neuropsychopharmacology (submitted).
Yubero-Lahoz S, Pardo R, Farre M, Mathuna B, Torrens M, Mustata C, Perez-Mañá C, Carbó M, De la Torre R. Contribution of CYP1A2 activity in 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) metabolism using caffeine as probe drug in humans. Br J Clin Pharmacol (submitted).
Yubero-Lahoz S, Ayestas MA Jr, Blough BE, Partilla JS, Rothman RB, de la Torre R, Baumann MH. Effects of MDMA and related analogs on plasma 5-HT: Relevance to 5-HT transporters in blood and brain.
Eur J Pharmacol. 2011 Nov 3. [Epub ahead of print].

Para comunicarse con Samanta Yubero-Lahoz mencionar a SIIC como referencia:
syubero@imim.es

---

Acerca del trabajo completo

DIFERENCIAS ENTRE LOS SEXOS EN LA INHIBICION DEL CYP2D6 INDUCIDA POR EL CONSUMO DE EXTASIS

Título original en castellano
DIFERENCIAS DE GENERO EN LA INHIBICION DEL CYP2D6 INDUCIDA POR LA MDMA

Autores
Samanta Yubero-Lahoz¹, Ricardo Pardo², Magí Farré³, Brian O'mahony⁴, Marta Torrens⁵, Cristina Mustata⁶, Clara Pérez-Mañá⁷, Marcel·lí Carbó⁸, Rafael De La Torre⁹
1 Estudiante Doctorado, Human Pharmacology and Clinical Neurosciences Research Group, Neuropsychopharmacology Program, Imim-Parc de Salut Mar, Barcelona, Spain., Universitat Pompeu Fabra (cexs-upf), Barcelona, España, Estudiante
2 Médico, Universitat Autònoma de Barcelona (uab), España.
3 Investigador Principal, Médico, 1human Pharmacology And Clinical Neurosciences Research Group, Neuropsychopharmacology Program, Imim-parc de Salut Mar, Barcelona, Spain 2universitat Autònoma, (udimas-uab), Barcelona, Spain
4 Phd, 3universitat Pompeu Fabra (cexs-upf), Barcelona, Spain
5 Investigador Principal, Médico, 4disorders By Use Of Substances Research Group, Neuropsychopharmacology Program, Imim-parc de Salut Mar; Iaps-hospital del Mar, Barcelona, Spain
6 Médico, Universitat Autònoma de Barcelona
7 Médico, Universitat Autònoma de Barcelona
8 Phd, Pharmd, 3universitat Pompeu Fabra (cexs-upf), Barcelona, Spain
9 Phd, Pharmd, 1human Pharmacology And Clinical Neurosciences Research Group, Neuropsychopharmacology Program, Imim-parc de Salut Mar, Barcelona, Spain, Director de Programa, Corresponding Auth

Acceso a la fuente original
Clinical Pharmacokinetics
http://link.springer.com/journal/40262

ua40317